[144] AvePoint, Inc. SEC Filing

Rhea-AI Filing Summary

Avidity Biosciences (NASDAQ: RNA) filed a Form 8-K announcing that the U.S. FDA granted Breakthrough Therapy designation to delpacibart zotadirsen ("del-zota") for Duchenne muscular dystrophy patients with mutations amenable to exon 44 skipping (DMD44).

The designation may provide rolling review and intensified FDA engagement. Avidity reaffirmed its plan to submit a BLA by year-end 2025; no financial figures were disclosed. The filing includes forward-looking-statement cautions that breakthrough status does not guarantee approval and that efficacy, safety or manufacturing issues could delay or block commercialization.

Positive

• FDA Breakthrough Therapy designation for del-zota signals strong preliminary efficacy and offers accelerated regulatory pathways.
• Company reiterates BLA submission by year-end 2025, suggesting development is on schedule.

Negative

• Filing emphasizes that breakthrough status does not guarantee approval; del-zota still faces clinical and regulatory risks.
• No financial or commercial projections were provided, leaving valuation impact partly speculative.

Insights

Biotech Equity Analyst

TL;DR: FDA breakthrough status materially de-risks del-zota and accelerates RNA’s regulatory timeline.

The breakthrough designation signals the FDA sees compelling early efficacy for exon 44-skipping DMD, granting Avidity earlier and more frequent agency interaction and potential priority review. For investors, this increases the probability of approval and shortens time-to-market, supporting valuation of the AOC platform. Milestone: BLA submission targeted for Q4-25, consistent with prior guidance. While designation is positive, the asset remains in clinical development and still faces safety, CMC and commercial execution risks.

Regulatory Affairs Specialist

TL;DR: Breakthrough Therapy offers regulatory advantages but provides no approval certainty.

Breakthrough status allows rolling review and senior-level FDA attention, which can cut several months off review time if the sponsor’s data package is robust. However, del-zota must still meet full efficacy and safety standards. The 8-K’s extensive risk disclosure properly notes potential clinical holds, manufacturing setbacks and reliance on third-party contractors. Investors should monitor upcoming data releases to confirm that benefit-risk remains favorable before BLA submission.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial 200 South 10th Street Suite 950 Richmond VA 23219	35000	654940.73	203233202	07/23/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/07/2022	Restricted Stock Grant	AVPT			35000	07/07/2022	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brown Brian Michael 4101 WELBY DR, MIDLOTHIAN VA 23113	Common	04/23/2025	35000	527813.98
Brown Brian Michael 4101 WELBY DR MIDLOTHIAN VA 23113	Common	05/23/2025	35000	638050.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the FDA grant to Avidity Biosciences (RNA)?

The FDA granted Breakthrough Therapy designation to delpacibart zotadirsen for Duchenne muscular dystrophy exon 44 skipping.

Why is Breakthrough Therapy designation important for RNA investors?

It enables accelerated development, rolling review and closer FDA guidance, potentially shortening time to market.

When does Avidity plan to file the BLA for del-zota?

The company expects to submit a Biologics License Application by year-end 2025.

Does Breakthrough Therapy designation ensure FDA approval?

No. Avidity notes the designation does not guarantee approval or expedited review; efficacy and safety must still be proven.

Were any financial metrics disclosed in the 8-K?

No. The filing focuses solely on the regulatory milestone; no revenue or earnings data were provided.